Lately, the team led by Prof. Yihua Zhang / Zhangjian Huang from the State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, in collaboration with Jiangsu Kanion Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial for AAPB injection. The trial will focus on its potential use in treating Acute Ischemic Stroke.
The AAPB project involves a collaboration between a university and an enterprise. The team led by Prof. Yihua Zhang, along with Prof. Zhangjian Huang and Assoc. Prof. Jianbing Wu from China Pharmaceutical University, is responsible for designing and selecting potential candidates. Jiangsu Kanion Pharmaceutical Co., Ltd. is in charge of conducting the later stages of preclinical research and evaluation. Both parties work together to promote and share the outcomes. In 2024, the university and the enterprise jointly applied for clinical trials for two injectable dosage specifications. The approval for the clinical trial was received in March, and China Pharmaceutical University ranked first for the project.
Pre-clinical results show that AAPB exerts dual effects of neuroprotection and cerebral blood flow improvement. Due to its innovative design and research, it has obtained a patent in China and regional patents in the U.S., Europe, Japan, and other nations, with a global patent strategy already in place. Developed at our university, AAPB is anticipated to emerge as a new top-tier anti-stroke medication with exclusive intellectual property rights in China soon.
